| Document |
Document Title |
|
WO/2022/237782A1 |
Provided are an amide derivative of formula (I), or a pharmaceutically acceptable salt thereof, or all stereoisomers, tautomers, and deuterated products thereof, and a pharmaceutical composition comprising the compound. The compound or c...
|
|
WO/2022/240876A1 |
Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I),...
|
|
WO/2022/238863A1 |
The invention refers to new quinoline-4-carboxamide derivatives, pharmaceutical compositions containing thereof and the use of the same as inhibitors of Ndc80 kinetochore subcomplex-MT binding and of kinetochore-MT binding, more preferab...
|
|
WO/2022/239919A1 |
The present specification pertains to a condensed polycyclic compound of chemical formula 1 and an organic light-emitting device including same.
|
|
WO/2022/238178A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein X, R1, R2, R3, R4 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to ...
|
|
WO/2022/232919A1 |
The present application relates to compounds, and uses thereof for example for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating a viral infection or disease. In an embodi...
|
|
WO/2022/233243A1 |
The present application provides an organic compound, and an electronic element and electronic apparatus comprising same, which belong to the technical field of organic electroluminescence. The structure of the organic compound is as sho...
|
|
WO/2022/235264A1 |
Applicants have developed novel methods and compositions for controlling, treating, preventing, or ameliorating arthropod infection and identifying kinin receptor agonists and antagonists. Novel compositions include one or more active ag...
|
|
WO/2022/234909A1 |
The present specification relates to an organic light-emitting device, a heterocyclic compound, and a composition for an organic layer of an organic light-emitting device.
|
|
WO/2022/233264A1 |
The present invention relates to a class of xanthine oxidase inhibitors, which are compounds as represented by general formula (I) or pharmaceutically acceptable salts thereof. The xanthine oxidase inhibitors have an excellent xanthine o...
|
|
WO/2022/229458A1 |
The present disclosure provides a compound of Formula (II), wherein R1 is an optionally substituted mono or bicyclic saturated, partly unsaturated or aromatic heterocyclyl comprising at least one nitrogen atom, and the other variables ar...
|
|
WO/2022/231268A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/230912A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases.　The present inventors hav...
|
|
WO/2022/231299A1 |
The present invention provides: a novel compound which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2022/228280A1 |
Provided are a crystal form of a compound represented by formula (I) and a preparation method therefor.
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/225914A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/225340A1 |
The present invention relates to: a compound for an organic optoelectronic element, wherein the compound is represented by chemical formula 1; a composition for an organic optoelectronic element, wherein the composition includes the comp...
|
|
WO/2022/223034A1 |
An SOS1 degradation agent and a preparation method therefor and an application thereof. Specifically, disclosed is a compound of formula I: S-L-E(I), wherein L is a linking chain, which links S and E by means of covalent bonds; E is a sm...
|
|
WO/2022/225238A1 |
The present invention relates to a heteroaryl derivative compound and a use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against HER2 and EGFR, and thus can be effectively used as a t...
|
|
WO/2022/224195A1 |
The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolones,...
|
|
WO/2022/224924A1 |
The present invention addresses the problem of providing: a nitrogen-containing heteroaryl compound which exhibits excellent bactericidal and anti-bacterial activity and excellent safety and which can be synthesized in an industrially ad...
|
|
WO/2022/223039A1 |
An SOS1 degrader, a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound of formula I: S-L-E (I), wherein S is a small molecule compound capable of inhibiting the activity of a...
|
|
WO/2022/225941A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/224975A1 |
Provided is a compound represented by formula (I) [in formula (I): R1 represents a substituted or unsubstituted C1-6 alkylsulfonyl group; R2 and R4 each independently represent a hydrogen atom or a substituted or unsubstituted C1-6 alkyl...
|
|
WO/2022/218289A1 |
This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for t...
|
|
WO/2022/219013A1 |
The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are ...
|
|
WO/2022/221194A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2022/221165A1 |
Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N- oxides, and salts thereof, wherein W, R1, R2, R3, Q1 and Q2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of ...
|
|
WO/2022/214645A1 |
The invention relates to processes for the preparation of relugolix of formula (VIII), or a pharmaceutically acceptable salt thereof. It also relates to intermediates of formula (IX), (X), and (XI) as defined herein useful in the synthes...
|
|
WO/2022/213905A1 |
The present application belongs to the field of organic materials, and relates to an organic compound, and an electronic element and an electronic device using same. The organic compound has a structure as represented by formula 1, and t...
|
|
WO/2022/214606A1 |
The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the ...
|
|
WO/2022/216626A1 |
Described herein are hydroxypyridine HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascul...
|
|
WO/2022/206797A1 |
Compounds of formula A, a method for using said compounds as an EGFR inhibitor, and a pharmaceutical composition comprising said compounds. The compounds can be used to treat, prevent or ameliorate diseases or conditions such as cancers ...
|
|
WO/2022/211281A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic material layer.
|
|
WO/2022/212489A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2022/206493A1 |
The present application belongs to the technical field of organic electroluminescence and relates to an organic compound, an electronic element comprising said organic compound, and an electronic apparatus. A structure of the organic com...
|
|
WO/2022/206389A1 |
The present application relates to the field of organic materials, and provides a nitrogen-containing compound and an electronic element comprising same, and an electronic device. The structure of the nitrogen-containing compound is as s...
|
|
WO/2022/210324A1 |
Provided are: a resin composition including a precursor of a cyclized resin and a base generator, wherein the base generated by the base generator is a base that cyclizes within the same molecule and becomes a tertiary amine, and the bas...
|
|
WO/2022/212914A1 |
The present disclosure provides methods of treating a TLR7- and/or TLR-mediated disease and also methods of treating disease in a multi-modal treatment regimen. The methods comprise administering an effective amount of a pharmaceutical c...
|
|
WO/2022/211211A1 |
The present specification relates to a heterocyclic compound of chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2022/211060A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound repre...
|
|
WO/2022/200786A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, includ...
|
|
WO/2022/200787A1 |
There is provided pharmaceutical compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, incl...
|
|
WO/2022/204683A1 |
Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of kinase-related disorders (including cancer, autoimmune disease, and Duchenne muscular dystrophy).
|
|
WO/2022/200785A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, i...
|
|
WO/2022/199449A1 |
The present application relates to an organic compound and an electronic device comprising same, and an electronic apparatus. The structural formula of the organic compound of the present application is represented by formula 1, and by a...
|
|
WO/2022/204227A1 |
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including h...
|
|
WO/2022/199367A1 |
The present invention relates to the technical field of pharmaceutical chemistry, and provides a dithiocarbamate compound and a preparation method therefor, a pharmaceutical composition, and applications. The dithiocarbamate compound pro...
|
|
WO/2022/199662A1 |
Provided are a compound represented by general formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, a deuterium isotopic derivative, pharmaceutically acceptable hydrate, solvate, salt, or eutectic t...
|
